Sugi Predict

Sugi Predict / Compounds / SCHEMBL950207

SCHEMBL950207

SCHEMBL950207

O=C1NC(=O)C2(N1)C(=O)N(C/C=C/c1ccc(Cl)c(Cl)c1)c1ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 4/20 0.37
▸ AKR1A1 P14550 3/20 0.37
▸ ALDH1A1 P00352 6/20 0.37
▸ MAPT P10636 4/20 0.37
▸ GAA P10253 2/20 0.37
▸ RCE1 Q9Y256 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ITGA4 P13612 1/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ ALDH2 P05091 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALPL P05186 1/20 0.34
▸ ALPI P09923 1/20 0.34
▸ ALPG P10696 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL949680 1.00 AKR1B1 (0.37) AKR1B1AKR1A1ALDH1A1MAPTGAA
SCHEMBL953677 1.00 AKR1B1 (0.37) AKR1B1AKR1A1ALDH1A1MAPTGAA
SCHEMBL950827 0.88 AR (0.34) AKR1B1AKR1A1ALDH1A1MAPTGAA
SCHEMBL949825 0.88 AR (0.34) AKR1B1AKR1A1ALDH1A1MAPTGAA
SCHEMBL950142 0.88 AR (0.34) AKR1B1AKR1A1ALDH1A1MAPTGAA
SCHEMBL4168480 0.84 ALDH1A1 (0.36) AKR1B1ALDH1A1MAPTGAARCE1
SCHEMBL13781378 0.82 CHRM5 (0.35) PTGDR2
SCHEMBL4157299 0.81 ALDH1A1 (0.36) ALDH1A1MAPTGAARCE1TSHR
SCHEMBL10802626 0.79 APAF1 (0.48) AKR1B1AKR1A1ALDH1A1MAPTTSHR
SCHEMBL4263796 0.79 ITGA4 (0.43) AKR1B1AKR1A1ALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 — — US claimed
US-20070185179-A1 New compounds ASTRAZENECA AB (SE) 2007-08-09 — — US claimed
US-7868181-B2 Compounds ASTRAZENECA AB (SE) 2011-01-11 — — US disclosed
US-7868181-B2 Compounds ASTRAZENECA AB (SE) 2011-01-11 — — US disclosed
US-7868181-B2 Compounds ASTRAZENECA AB (SE) 2011-01-11 — — US disclosed
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-07-09 — — US disclosed
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-07-09 — — US disclosed
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-07-09 — — US disclosed
US-20090137650-A1 New Compounds LEUNG CARMEN 2009-05-28 — — US disclosed
US-20090137650-A1 New Compounds LEUNG CARMEN 2009-05-28 — — US disclosed
US-20090137650-A1 New Compounds LEUNG CARMEN 2009-05-28 — — US disclosed
EP-2013215-A2 NOVEL SPIRO[IMIDAZOLIDINE-4,3'-INDOLE]-2,2',5(1'H)-TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 AstraZeneca AB (SE) 2009-01-14 — — EP disclosed
WO-2007091946-A1 USE OF SPIRO [ IMIDAZOLIDINE-4, 3'-INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 — — WO disclosed
WO-2007091948-A2 NOVEL SPIRO [IMIDAZOLIDINE-4, 3´-INDOLE] 2, 2´,5´(1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 — — WO disclosed
WO-2007091948-A2 NOVEL SPIRO [IMIDAZOLIDINE-4, 3´-INDOLE] 2, 2´,5´(1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 — — WO disclosed
WO-2007091947-A2 NOVEL SPIRO[IMIDAZOLIDINE-4,3'-INDOLE]-2,2',5(1'H)-TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 — — WO disclosed
WO-2007091947-A2 NOVEL SPIRO[IMIDAZOLIDINE-4,3'-INDOLE]-2,2',5(1'H)-TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 — — WO disclosed
US-20070185179-A1 New compounds ASTRAZENECA AB (SE) 2007-08-09 — — US disclosed
US-20070185179-A1 New compounds ASTRAZENECA AB (SE) 2007-08-09 — — US disclosed
US-20070185179-A1 New compounds ASTRAZENECA AB (SE) 2007-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137650-A1 New Compounds CLIC1, AQP1, AVPR2 AKR1B1 847/4885AKR1A1 842/4885ALDH1A1 1551/4885
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV2, TRPV3 AKR1B1 366/4885AKR1A1 317/4885ALDH1A1 502/4885
US-20070185179-A1 New compounds CLIC1, AQP1, AVPR2 AKR1B1 847/4885AKR1A1 842/4885ALDH1A1 1551/4885
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 AKR1B1 344/4885AKR1A1 310/4885ALDH1A1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.